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Purpose: Oxidative stress is a risk factor for the onset and progression of primary open-angle glaucoma (POAG), but the
exact molecular basis remains unknown. Here, we investigated the mechanisms for Pro370Leu mutant myocilin to induce
mitochondrial dysfunction and subsequent reactive oxygen species (ROS) generation in trabecular meshwork (TM) cells
obtained from POAG individuals.
Methods: Primary non-diseased human TM cultures were transfected with pIRES-EGFP (Mock), pIRES-wild-type (WT),
or pIRES-Pro370Leu mutant myocilin. Transfection efficiency and myocilin subcellular localization were determined by
polymerase chain reaction (PCR), western blot analysis, and confocal microscopy. ROS levels as well as free Ca2+
concentrations in cytoplasm ([Ca2+]c) and mitochondria ([Ca2+]m) were examined by 2’7’-dichlorofluorescein diacetate
(H2-DCF-DA), Fluo-3 acetoxymethyl ester (Fluo-3/AM), and Rhod-2 acetoxymethyl ester (rhod-2/AM), respectively,
using flow cytometry. Mitochondrial functions were revealed by changes in mitochondrial membrane potential (ΔΨm)
and  ATP  production,  which  were  found  by  fluorescent  probe  5,5′,6,6’-tetrachloro-1,1’3,3′-tetraethylbenzimid
azolocarbocyanine iodide (JC-1) and a luciferin/luciferase-based ATP assay, respectively.
Results: Both WT and Pro370Leu mutant myocilin are localized in the mitochondria of TM cells as indicated using
confocal microscopy and western blot analysis. Overexpression of WT myocilin decreases ΔΨm, which is further reduced
by Pro370Leu mutant myocilin. TM cells that overexpressed Pro370Leu mutant myocilin have greater cell death, higher
endogenous ROS, [Ca2+]c, and [Ca2+]m levels, and lower ATP production, and yet, these effects are not seen in the
overexpression of WT myocilin.
Conclusions: Our findings suggested that Pro370Leu mutant myocilin causes mitochondrial defects, which may lead to
TM cell dysfunction and even cell death. Therefore, preventive measures targeting mitochondrial protection may delay
the onset of glaucoma in individuals carrying the Pro370Leu myocilin mutation.
Glaucoma  is  the  second  leading  cause  of  irreversible
blindness worldwide, which affects approximately 70 million
people [1]. Primary open-angle glaucoma (POAG), the most
common form of this disease, contributes to a large proportion
of blindness cases in the elderly [2-6].
POAG  is  associated  with  intraocular  pressure  (IOP)
elevation, which is caused by abnormal resistance of aqueous
outflow through the trabecular meshwork (TM), a specialized
tissue  lining  the  outflow  pathway  of  the  eye  [7,8].  The
mechanisms that lead to such abnormalities in TM are largely
unknown.  Possible  means  include  gene  mutations  (e.g.,
myocilin,  optineurin)  [9,10],  vascular  alterations  [11,12],
mechanical injuries [13-16], and local oxidative stress [17,
18]. Elevated IOP leads to progressive optic neuropathy and
ganglion cell death in the neural retina that often result in
irreversible loss of vision [13-16].
Myocilin  is  also  known  as  “TIGR”  for  trabecular
meshwork-inducible  glucocorticoid  response.  Mutation  of
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this gene was first reported to associate with juvenile-onset
open-angle glaucoma (JOAG) in 1997 [19]. Later, more than
70 mutation sites in the myocilin gene were identified to be
related to the pathogenesis of approximately 3% of familial
autosomal dominant adult-onset open-angle glaucoma and a
greater  proportion  of  JOAG  [20].  Among  the  identified
mutations, the Pro370Leu mutation (OMIM 601652; allelic
variant  0.007)  is  responsible  for  one  of  the  most  severe
glaucoma phenotypes [21-24]. These patients have high IOP,
typical glaucomatous cupping of the optic disc, and a thinner
nerve  fiber  layer  and  are  unresponsive  to  standard
pharmacological  treatments  [25].  In  this  study,  we
investigated how Pro370Leu mutant myocilin affects the TM
cells.
Myocilin is a signal peptide secretary protein [26-29]. It
has both intracellular and intercellular functions [30,31] and
can be found in various organelles such as the endoplasmic
reticulum (ER), Golgi apparatus [32-38], and mitochondria
[39-42]. Myocilin is imported into the mitochondria and the
specific transporter is currently unknown [42]. It localizes on
inner and outer membranes as well as in the intermembranous
space but not in the mitochondrial matrix [42]. Although the
myocilin transcript and protein are ubiquitously expressed in
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815multiple  ocular  tissues  [43],  its  interaction  with  the
mitochondria  appears  to  be  cell  specific.  Myocilin-
mitochondria interaction is seen in TM cells and astrocytes
but not in corneal ﬁbroblasts [40,41]. These findings prompt
us  to  hypothesize  that  myocilin  mutations  may  alter
mitochondrial  function  in  TM  cells,  which  explains  the
specificity of myocilin mutations to glaucoma.
Here, we report that TM cells that overexpress Pro370Leu
mutant  myocilin  demonstrate  features  of  mitochondrial
dysfunction  including  increased  cellular  reactive  oxygen
species  (ROS)  and  decreased  mitochondrial  membrane
potential (ΔΨm) and ATP production as well as dysfunction
in  calcium  regulation.  These  findings  indicate  Pro370Leu
mutant myocilin may increase vulnerability of TM cells to
various cellular insults and cause impaired functioning.
METHODS
Materials: All tissue culture reagents were obtained from
Gibco  BRL  (Gaithersburg,  MD).  The  luciferin/luciferase-
based ATP assay kit was purchased from Sigma (St. Louis,
MO).  2’,7’-dichlorodihydrofluorescin  diacetate  (H2-DCF-
DA),  5,5′,6,6’-tetrachloro-1,1’3,3′-tetraethylbenzimid
azolocarbocyanine  iodide  (JC-1),  Hoechst33342,
MitoTracker Red, Fluo-3 acetoxymethyl ester (Fluo-3/AM)
and Rhod-2 acetoxymethyl ester (Rhod-2/AM; the dyes) were
obtained from Molecular Probes (Carlsbad, CA). Polyclonal
rabbit anti-human myocilin (N-15) antibody and polyclonal
goat  anti-human  COX  IV  antibody  were  purchased  from
Santa Cruz Biotechnology (Santa Cruz, CA).
Plasmid construction: The full-length myocilin cDNA clone
has been described in our previous article and in another study
[44,45].  Briefly,  EcoRI  and  BamHI  restriction  enzyme
cleavage sites were added to the 5′ and 3′ end of the myocilin
cDNA by polymerase chain reaction (PCR). The obtained
fragment  was  cloned  into  mammalian  expression  plasmid
(pIRES and pIRES-EGFP; Clontech, Palo Alto, CA). We
generated Pro370Leu mutations with the QuikChange site-
directed mutagenesis kit (Stratagene, La Jolla, CA) according
to the manufacturer's instructions. The specific PCR primers
for Pro370Leu mutagenesis were as follows: 5′-CTA CCA
CGG ACA GTT CCT GTA TTC TTG GGG TGG CTA-3′
and 5′-TAG CCA CCC CAA GAA TAC AGG AAC TGT
CCG TGG TAG-3′. The sequence of the Pro370Leu myocilin
mutant plasmid was verified using DNA sequencer to confirm
correct insertion and the absence of undesirable mutations.
Tissue  procurement  and  cell  culture:  Procurement  of  the
human tissue was performed according to the tenets of the
Declaration of Helsinki. Normal human eyes were obtained
from  the  Zhongshan  Ophthalmic  Center  Eye  Bank  in
Guangzhou, China as we mentioned in our previous studies
[18,46]. The procurement of tissue was approved by the IRB
Committee  at  the  Sun  Yat-sen  University  at  Guangzhou.
Normal TM cells were derived from 5 human donor eyes with
no known ocular diseases. These eyes were obtained within
24  h  after  death  and  were  dedicated  for  corneal
transplantation. The ages of the donors ranged from 20 to 40
years.
The TM cultures were prepared as described before [18,
46-49]. Briefly, human TM was carefully dissected from the
anterior segments and the whole corneal layer of the donor
eyes.  The  explants  were  placed  in  24  well  culture  plates
(Corning  Costar,  Cambridge,  MA)  containing  Dulbecco’s
modified  Eagle’s  medium  (DMEM),  which  was
supplemented  with  15%  fetal  bovine  serum,  2  mM  L-
glutamine, penicillin (100 U/ml), and streptomycin (100 μg/
ml).  Cells  gradually  migrated  from  the  TM  explants  and
formed a confluent monolayer in approximately 10–14 days.
Fourth- or fifth-passage cells were used for all the studies
described here. The TM cells were seeded at a density of
1×105 cells per well using six-well tissue culture plates, and
micrographs of the cultures were taken three days post seeding
at approximately 80% confluency.
The identity of the TM cells has been characterized in our
previous publications using immunocytochemical staining of
fibronectin, laminin, and neuron-specific enolase [18,46], and
by  the  increased  myocilin  expression  after  exposure  to
dexamethasone (10–7 M) for three days [50,51].
Gene transfection: Fourth- or fifth-passage TM cells grown
to about 80%–85% confluence were incubated for 6 h with
1  μg  of  pIRES-EGFP-WT,  pIRES-WT,  pIRES-EGFP-
Pro370Leu,  or  pIRES-Pro370Leu  myocilin  expression
plasmids  in  the  presence  of  Lipofectamine  (0.3%  v/v;
Invitrogen).  The  cells  were  then  washed  and  cultured  for
another  24  h  or  48  h.  The  efficiency  of  transfection  was
estimated by transiently transfecting the cells with pIRES-
EGFP vector, and the percentage of EGFP-positive cells were
analyzed using flow cytometry. The transfection efficiency
was about 38%–46%. Also, TM cells transfected with the
pIRES (Mock) plasmid was used as a negative control.
Myocilin mRNA measurement: Myocilin mRNA expression
was  analyzed  by  reverse  transcriptase-polymerase  chain
reaction (RT–PCR). Total mRNA from TM samples with or
without  transfection  were  isolated  using  RNeasy  reagents
(Qiagen,  Valencia,  CA)  according  to  the  manufacturer’s
protocol. First-strand cDNA was synthesized using iScript
cDNA synthesis kit (Bio-Rad, Hercules, CA). RT–PCR was
performed using iTaq polymerase (Bio-Rad) at an annealing
temperature of 59 °C for 30 cycles for both myocilin and
Glyceraldehyde-3-phosphate  dehydrogenase  (GAPDH)
primers. The primer sequences used in PCR reactions for the
myocilin gene are (sense) 5′-CTG GAA ACC CAA ACC
AGA GA-3′ and (antisense) 5′-AAA TTC GGG AAG CAG
GAA CT-3′. GAPDH was used as the internal RNA loading
control,  and  the  samples  where  no  reverse  transcriptase
(NRTs) was added to the PCR experiments were used as
negative controls to confirm that the amplification was RNA
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electrophoresis.
Mitochondrial isolation and total cell lysate preparation: For
mitochondrial  protein  extraction,  mitochondria  from  TM
cultures were isolated using a mitochondria isolation kit for
cultured    cells    (Pierce   Chemical   Co.,   Rockford,   Il).
Briefly, after being transfected with pIRES-EGFP plasmid
(Mock),  pIRES-EGFP-WT  myocilin,  and  pIRES-EGFP-
Pro370Leu  for  48  h,  three  75  cm2  culture  flasks  of  85%
confluent cells were homogenized in ice-cold buffer (225 mM
mannitol, 75 mM sucrose, 1 mM EGTA, 5 mM HEPES, 2 mg/
ml  fat-free  bovine  serum  albumin  [BSA],  and  protease
inhibitor cocktail [Roche Diagnostics, Branchburg, NJ]) with
30 up-and-down strokes using a motor-driven Teflon pestle
that is tight-fitted to a Dounce homogenizer (Kontes Co.,
Vineland, NJ). The homogenate was centrifuged at 1,000x g
for 10 min at 4 °C, and the resulting supernatant was layered
onto 5 ml of 7.5% Ficoll medium (Sigma, St. Louis, MO) after
being layered onto 5 ml of 10% Ficoll medium (0.3 M sucrose,
50  μM  EGTA,  and  10  mM  HEPES)  and  centrifuged  at
79,000x  g  for  30  min.  Mitochondrial  pellets  were  re-
suspended in 500 μl of ice-cold mitochondrial buffer in a pre-
weighed 0.5 ml tube and centrifuged. The supernatant was
then  discarded  and  the  pellet  weight  estimated.  The
mitochondrial pellets were then lysed in 0.5 ml Cytobuster
lysis buffer (Novagen, Madison, WI) and centrifuged, and
protein concentrations were estimated using Dc Protein Assay
Kit (Bio-Rad).
For  total  cellular  protein  preparation,  TM  cells
transfected  with  pIRES  plasmid  (Mock),  pIRES-WT
myocilin, or pIRES-Pro370Leu mutant myocilin for 48 h were
lysed in 0.5 ml Cytobuster lysis buffer and centrifuged, and
protein  concentrations  were  estimated  using  DC  Protein
Assay Kit.
Western blot analysis: Forty micrograms of mitochondrial
protein or total cellular protein was separated by SDS–PAGE
and  transferred  onto  nitrocellulose  membranes  (Bio-Rad).
After blocking with 5% (w/v) dried milk, membranes were
incubated with polyclonal rabbit anti-human myocilin (N-15)
antibody (1:200) and polyclonal goat anti-human COX IV
antibody  (1:200;  Santa  Cruz  Biotechnologies)  at  4  °C
overnight  followed  by  washing  and  incubation  with
Horsheradish peroxidase (HRP)-conjugated goat anti-rabbit
IgG (1:200; Bio-Rad) for 1 h at room temperature. Bound
antibody was determined using the Bio-Rad ECL detection
system.
Morphological  analysis  of  trabecular  meshwork  cultures
after transfection: TM cells seeded at a density of 1×105 cells
per well in six-well plates were transfected for 24 h with
pIRES-EGFP plasmid (Mock), pIRES-EGFP-WT myocilin,
or pIRES-EGFP-Pro370Leu mutant myocilin. Phase contrast
micrographs were taken to examine morphological changes
after transfection.
Some of the cells were seeded in a 35 mm2 Petri dish and
transfected  with  pIRES-EGFP  plasmid  (Mock),  pIRES-
EGFP-WT  myocilin,  or  pIRES-EGFP-Pro370Leu  mutant
myocilin  for  8  h.  Cells  were  either  stained  with  1  μg/ml
Hoechst33342 to illustrate the nuclei or labeled with 50 nM
of MitoTracker Red to show the mitochondria. The staining
pattern was visualized by Zeiss 100M confocal microscope
(Carl Zeiss Jena GmbH, Jena, Germany).
Measurement of reactive oxygen species: Cellular oxidative
stress was determined by cytoplasmic ROS levels [52,53].
Briefly, cells transfected with pIRES plasmid (Mock), pIRES-
WT myocilin, or pIRES-Pro370Leu mutant myocilin and non-
transfected cells were trypsinized and re-suspended in freshly
prepared H2-DCF-DA (0.4 μM) at a density of 2×106 cells/ml
at 37 °C in the dark for 30 min. H2-DCF-DA penetrates into
cells and emits green fluorescence upon oxidation through a
reaction with H2O2 and to a certain extent with NO. H2-DCF-
DA-loaded cells were rinsed twice with PBS and analyzed
immediately by flow cytometry at 488 nm excitation and 530
nm emission. Ten thousand cells were routinely collected, and
data were expressed as the median fluorescence intensity in
arbitrary units from the average of at least three repeated
experiments.
Measurement of calcium levels in the cytoplasm ([Ca2+]c) and
mitochondria  ([Ca2+]m)  of  trabecular  meshwork  cells:
Changes  in  [Ca2+]c  and  [Ca2+]m  were  measured  with  the
fluorescent probe fluo-3/AM (dissociation constant [Kd] ~400
nM)  and  Rhod-2/AM  (Kd  ~570  nM),  respectively,  as
described previously [46,54-56]. Fluorescence intensity of
labeled cells was measured using flow cytometry.
The cells were cultured in six-well plates at a density of
1×105  cells  per  well.  After  being  transfected  with  pIRES
plasmid  (Mock),  pIRES-WT  myocilin,  and  pIRES-
Pro370Leu mutant myocilin for 24 h, TM cells were loaded
with either 1 μM fluo-3/AM for 30 min or 1 μM rhod-2/AM
for 1 h. The cells were then trypsinized, washed twice with
cold PBS, re-suspended in 200 μl PBS, and then immediately
analyzed by flow cytometry at an excitation wavelength of
488 nm and an emission wavelength of 525 nm for fluo-3/AM
and  an  excitation  wavelength  of  549  nm  and  emission
wavelength  of  581  nm  for  Rhod-2/AM.  The  fluorescent
intensity of 10,000 labeled cells was routinely collected for
each  analysis  and  the  data  expressed  as  the  median
fluorescence intensity in arbitrary units from the average of at
least three repeated experiments.
Measurement of cellular ATP: ATP levels were determined
using a luciferin/luciferase-based ATP assay. Briefly, cells
grown in 24-well plates were transfected with pIRES plasmid
(Mock), pIRES-WT myocilin, and pIRES-Pro370Leu mutant
myocilin for 24 h. After removal of the treatments, the cell
membrane was permeabilized by 100 μl of somatic cell ATP-
releasing  reagent  (FL-SAR;  Sigma-Aldrich  Co.,  St  Louis,
MO) and was allowed to react with 100 μl of ATP Assay Mix
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817Reagent (FLAA; Sigma-Aldrich Co.) containing luciferin and
luciferase. After the 10 min incubation at room temperature,
luminescence was measured with a 0.5 s integration time
using  a  luminometer  (Orion  II  Luminometer;  Berthold
Detection Systems, Oak Ridge, TN). The cellular ATP level
was expressed as the percentage of luminescence intensity of
normal human TM cells.
Measurement  of  mitochondrial  membrane  potential:  JC-1
was used to demonstrate the changes in the mitochondrial
membrane potential (ΔΨm) in TM cells. JC-1 is a lipophilic
and cationic dye, which permeates plasma and mitochondrial
membranes.  The  dye  fluoresces  red  when  aggregates  in
healthy mitochondria with high membrane potential, whereas
it  appears  in  monomeric  form  and  fluoresces  green  in
mitochondria with diminished membrane potential. JC-1 was
freshly diluted in serum-free DMEM to a final concentration
of 1 μg/ml and was added to suspending transfected (pIRES,
pIRES-WT  myocilin,  and  pIRES-Pro370Leu  mutant
myocilin for 24 h) and non-transfected cells at a density of
2×106 cells/ml. After incubation for 20 min at 37 °C in the
dark, all samples were rinsed twice in PBS and analyzed
immediately by flow cytometry at 488 nm excitation. Data
were collected at 530 nm emission for green fluorescence of
the JC-1 monomer on the filter 1 (FL1 detector) and at 590
nm for red fluorescence of JC-1 aggregates on the filter 2 (FL2
detector).  Results  were  presented  in  relative  aggregate  to
monomer  (red:green)  fluorescence  intensity  ratio.  Cell
numbers in quadrant 4 (Q4; green fluorescent only) were also
recorded.
Statistical analysis: For quantitative analyses, we conducted
triplicate experiments on all five TM samples, and data from
15 trials were averaged. For qualitative analysis, all images
were generated from the TM cell of one donor to represent
similar changes observed in four other donors’ TM cells.
Numerical results were analyzed using one-way ANOVA and
expressed  in  mean±standard  error  (SE).  Differences  were
considered statistically significant at p<0.05.
RESULTS
Morphological  changes  of  trabecular  meshwork  cells
overexpressing  Pro370Leu  mutant  myocilin:  In  phase-
contrast micrographs, TM cells that were transfected with
Pro370Leu mutant myocilin for 24 h looked unhealthy and
exhibited cell shrinkage and shedding (Figure 1). Fewer cells
were seen in these cultures in part due to cell death and cell
detachment.  TM  cells  with  WT  myocilin  transfection
maintained a relatively healthy appearance.
Increased  expression  of  myocilin  after  transfection:  To
determine the transfection efficiency, we transfected the TM
cells  with  pIRES-EGFP  plasmid  and  EGFP-positive  cells
were quantified using flow cytometry. The TM cells from all
five  donors  showed  similar  responses  to  P370L  myocilin
transfection that EGFP-positive cells comprised 38%–46% of
total cells in the culture (Figure 2).
Figure 1. Morphology change of TM cells after Pro370Leu mutant
myocilin  transfection.  Phase-contrast  light  micrographs  show
healthy  looking  TM  cells  in  non-transfected  (Control),  pIRES
transfected  (Mock),  or  pIRES-WT  myocilin  transfected  (WT)
cultures. However, TM cells demonstrate an unhealthy, degenerative
appearance  after  transfection  with  pIRES-Pro370Leu  mutant
myocilin (P370L) for 24 h. Fewer cells are seen in these cultures in
part due to cell death and cell detachment. Scale bar=30 μm.
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818We then transfected the TM cells with vector carrying
WT or Pro370Leu mutant myocilin. After transfection for 48
h,  the  expression  of  WT  or  Pro370Leu  was  increased  as
determined by RT–PCR and western blot analysis (Figure 3).
Myocilin  co-localizes  with  mitochondria:  The  confocal
images  in  Figure  3  show  the  mitochondrial  staining  with
Figure 2. The efficiency of myocilin transfection. The efficiency of
transfection  was  estimated  in  TM  cells  transfected  with  pIRES-
EGFP (Mock), pIRES-WT myocilin (WT), or pIRES-Pro370Leu
mutant  myocilin  (P370L)  by  counting  the  percentage  of  EGFP-
positive cells using flow cytometry analysis. The non-transfected TM
cells are used as the control. The transfection efficiency was about
38%–46%.
MitoTracker  Red,  a  mitochondria  specific  dye,  after
transfection  with  plasmids  for  48  h.  From  the  confocal
micrographs, both EGFP-WT and EGFP-Pro370Leu mutant
myocilin  transfected  cells  had  demonstrated  overlapping
EGFP signals (green fluorescence) and mitochondrial staining
(red  fluorescence).  In  cells  transfected  with  pIRES-EGFP
(Mock), however, EGFP was expressed everywhere inside the
cells, and no overlay with mitochondria was observed. This
data  indicated  that  myocilin  co-localizatized  with
mitochondria in TM cells.
Figure 3. Increased expression of myocilin after transfection. RT-
PCR and western blot show that transfection of WT or Pro370Leu
(P370L) mutant myocilin increase both myocilin mRNA and protein
levels in TM cells after 48 h. GAPDH was used as the internal loading
control in RT–PCR while β-actin and cytochrome C oxidase (COX
IV) were used as internal loading controls in western blot analysis
for total cell lysate and mitochondrial lysate, respectively. Confocal
images  show  myocilin  co-localized  with  mitochondria.  After
transfection for 8 h, non-fixed TM cells were immunolabeled with
MitoTracker  Red,  a  mitochondria  specific  dye.  Confocal
microscopic analyses show that both pIRES-EGFP-WT myocilin
(WT)  and  pIRES-EGFP-Pro370Leu  mutant  myocilin  (P370L)
transfected  cells  have  overlapping  EGFP  staining  (green
fluorescence)  and  mitochondria  staining  (red  fluorescence).
However,  the  green  fluorescence  from  pIRES-EGFP  (Mock)  is
diffusive within the cells with no overlapping with mitochondrial
staining.  Our  result  indicates  co-localization  of  myocilin  and
mitochondria in TM cells. Scale bar=30 μm.
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generation,  increases  calcium  levels  in  the  cytoplasm
([Ca2+]c)  and  mitochondria  ([Ca2+]m):  We  next  examined
whether myocilin affects the function of mitochondria by
measuring  ROS,  [Ca2+]c,  and  [Ca2+]m  levels  in  TM  cells
overexpressing WT or Pro370Leu mutant myocilin. In Figure
4, we present evidence determined by flow cytometry that
Pro370Leu  mutant  myocilin  significantly  increased  ROS
generation (2.05±0.94 fold) as well as [Ca2+]c (3.17±0.64 fold)
and [Ca2+]m (1.92±0.74 fold) levels in TM cells compared to
WT myocilin.
Pro370Leu mutant myocilin causes greater endogenous ATP
and mitochondrial membrane potential reduction compared
to  wild  type  myocilin:  ATP  depletion  and  mitochondrial
depolarization (decrease in ΔΨm) are the major events in
mitochondrial dysfunction. Figure 5 shows that there was a
decrease  in  endogenous  ATP  levels  in  TM  cells  after
Pro370Leu mutant myocilin transfection compared to those
with WT myocilin transfection (p<0.05). In addition, TM cells
after Pro370Leu mutant myocilin transfection had a lower
ΔΨm  compared  to  those  with  WT  myocilin  transfection
(p<0.05; Figure 6).
DISCUSSION
Recently, we reported a Pro370Leu mutation of the myocilin
gene in a large Chinese autosomal dominant JOAG family
(GZ.1) encompassing 56 family members with 19 of them
exhibiting JOAG. All these JOAG-affected family members
present  similar  clinical  symptoms  of  high  IOP,  typical
glaucomatous cupping of the optic disc, and a thinner nerve
fiber layer and are unresponsive to standard pharmacological
treatments [25]. From these patients, we were the first to report
that Pro370Leu mutant myocilin enhances ER stress response
in human TM cells [45], but how Pro370Leu mutant myocilin
affects mitochondrial function is still unclear. Another study
has indicated a mutation of this gene causes apoptosis in TM
cells [24]. Here, we illustrate the interaction of Pro370Leu
myocilin  with  mitochondria  and  proposed  a  possible
mechanism that may lead to TM cell damage.
In  this  study,  we  provide  evidence  of  an  association
between myocilin and mitochondria and found that TM cells
expressing Pro370Leu mutant myocilin exhibit mitochondrial
dysfunction that is not seen in cells expressing WT myocilin.
Sakai et al. showed that the myocilin enters the mitochondria
and interacts with the mitochondrial membranes [42]. His
findings  corroborates  results  from  immunogold  labeling,
fluorescence  labeling,  and  subcellular  fractionation
experiments that myocilin is associated with mitochondria in
TM  cells  [39-42].  However,  myocilin  localization  in  the
mitochondria is not observed in corneal fibroblasts or in the
mouse liver. The regulatory mechanisms of such cell-specific
localization of myocilin require further investigation, but this
phenomenon  makes  TM  cells  more  sensitive  to  any
undesirable  effects  of  myocilin  mutations  on  the
mitochondria.
The fact that both WT and Pro370Leu mutant myocilin
sit on the mitochondria raises the question whether these two
proteins have different effects to the function of mitochondria.
Because  growing  evidence  has  shown  the  relationship
between  oxidative  stresses  and  exacerbated  glaucomatous
conditions [17,18,57,58], we compared ROS levels in the
normal human TM cells and those cells after WT myocilin or
Pro370Leu mutant myocilin transfection. We found that the
Figure 4. Pro370Leu mutant myocilin induces ROS generation and
increases calcium levels in the cytoplasm and mitochondria in TM
cells as estimated using flow cytometry. A: The oxidation sensitive
fluorescence dye, H2-DCF-DA, was used to measure the ROS levels
in TM cells. TM cells transfected with Pro370Leu (P370L) mutant
myocilin transfection show 2.05 fold (±0.94) stronger H2-DCF-DA
fluorescent intensity than those transfected with WT myocilin (WT),
indicating an increase in ROS generation after Pro370Leu mutant
myocilin transfection compared to WT myocilin transfection. B,C:
The [Ca2+]c and [Ca2+]m indicators, fluo-3/AM and Rhod-2, were
used  to  illustrated  the  free  Ca2+  levels  in  the  cytoplasm  and
mitochondria, respectively. There was a 3.17 fold (±0.64) increase
in [Ca2+]c and 1.92 fold (±0.74) increase in [Ca2+]m after Pro370Leu
mutant myocilin (P370L) transfection compared to WT myocilin
transfection (WT). Data are expressed as fold changes in fluorescent
levels of transfected TM cells to non-transfected TM cells (Control).
Results are expressed as the mean±SE of three repeated experiments
done in triplicate. An asterisk indicates a significant difference from
non-transfected cells at p<0.05.
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820endogenous ROS level is higher in the TM cells following
Pro370Leu mutant myocilin transfection compared to those
with  WT  myocilin  transfection,  indicating  that  increased
oxidative  stress  is  associated  with  the  pathogenesis  of
Pro370Leu mutant myocilin in POAG patients. There is a
general  consensus  that  cumulative  oxidative  damage  is
responsible  for  general  aging  [59-62].  Although  many
individuals with POAG were young adults in the GZ.1 family
[25], the higher ROS levels in the TM cells with Pro370Leu
mutant myocilin gene could possibly accelerate the aging
process in this region, which may in part contribute to the
progression of POAG.
Myocilin  increases  both  [Ca2+]c  and  [Ca2+]m,  possibly
through  the  disregulation  of  calcium  channels.  Calcium-
dependent contractibility of TM cells control outflow of the
aqueous humor, which maintains IOP. Failure in closing the
L-type calcium channel leads to an excessive influx of Ca2+,
causing membrane depolarization, TM contraction, reduced
outflow,  and  IOP  elevation.  Though  a  direct  interaction
between Pro370Leu mutant myocilin and the L-type calcium
channel  is  not  conclusive  from  our  data,  it  is  a  possible
explanation to our observation.
On top of its ATP generation ability, the mitochondria
also  plays  a  part  in  modulating  the  amplitude  and
spatiotemporal organization of Ca2+ signals through rapidly
accumulating and releasing Ca2+ [63,64]. However, excessive
cytoplasmic Ca2+ leads to mitochondrial Ca2+ overload, which
triggers  ROS  overproduction,  mitochondrial  membrane
depolarization, and ATP production inhibition, all hallmark
Figure 5. Pro370Leu mutant myocilin decreases ATP levels in TM
cells. Luciferin/luciferase-based ATP assay indicates that the ATP
level in TM with Pro370Leu mutant myocilin (P370L) transfection
is 57.7% lower compared to WT myocilin transfection (WT). The
ATP levels in non-transfected TM cells (Control) are arbitrarily
defined as 100%. The results are expressed as a mean percentage of
the ATP levels to the control, error bars represent SE of three repeated
experiments done in triplicate. An asterisk indicates a significant
difference from non-transfected cells at p<0.05.
events of mitochondrial dysfunction and eventual apoptosis
[65,66].
Studies  showed  that  myocilin  is  imported  into  the
mitochondria and may target the inner and outer membranes
and inter-membrane space [42]. However, the structure of
myocilin  does  not  seem  to  have  a  typical  NH2-terminal
mitochondrial-targeting presequence. Myocilin is predicted to
contain a potential mitochondrial transit peptide at its NH2-
terminus  (amino  acid  residues  1–47)  using  the  PCGene
program (IntelliGenetics Inc., Mountain View, CA) base on
Figure  6.  Pro370Leu  mutant  myocilin  further  decreases
mitochondrial membrane potential in TM cells. ΔΨm was examined
using flow cytometry with the fluorescence indicator, JC-1. The dye
fluoresces red when aggregates in healthy mitochondria with high
membrane potential, whereas it appears in monomeric form and
fluoresces  green  in  mitochondria  with  diminished  membrane
potential. The cells number in the Q4 area (green fluorescence)
indicates the number of cells with low ΔΨm. The histogram shows
the relative decrease of ΔΨm to the non-transfected cell (Control).
A: The ΔΨm is 3.03 fold (±0.90) lower in TM cells transfected with
Pro370Leu  mutant  myocilin  (P370L)  compared  to  TM  cells
transfected with WT myocilin (WT) while there is a 2.44 fold (±0.87)
reduction in WT compared to Mock. B: Pro370Leu mutant myocilin
transfected TM cells have a significantly lower red to green ratio,
and more cells show green fluorescence (cells in Q4 area), indicating
Pro370leu mutant myocilin causes a greater mitochondria membrane
depolarization. Results are expressed as the mean fold decrease in
relative aggregate, a monomer (red:green) ratio of transfected TM to
non-transfected  TM  cells.  The  error  bars  represent  SE  of  three
repeated  experiments  done  in  triplicate.  An  asterisk  indicates  a
significant difference from non-transfected cells at p<0.05.
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821the charge transition and R(2) weak rule [67]. Also, both the
NH2- and COOH-termini of myocilin contain a lysine- and
arginine-rich  mitochondrial  tethering  domain  (amino  acid
residues 33–46 and 460–504) [68]. Like the predictions for
other  mitochondrial  outer  membrane  proteins,  some  data
showed the α-helical transmembrane segment of the NH2-
terminal is the main contributor for myocilin to incorporate
into mitochondrial membranes, while the beta-sheet segment
at the COOH-terminus play a comparatively minor role [42,
69-71].  However,  the  exact  targeting  sequence  for
mitochondrial translocation of myocilin is still unclear.
Myocilin appears to be imported into the mitochondria
with the aid of a high molecular weight translocator complex
in the outer and inner mitochondrial membranes [42], which
has  been  demonstrated  with  other  mitochondrial  proteins
[70,72-75]. Mutation in myocilin alters the protein structure
and conformation [76-78]. Since Pro370Leu is located within
the  highly  conserved  Olfactomedin  (OLF)-domain  at  the
COOH-terminus  of  myocilin  [79],  it  is  possible  that  the
mutation  changes  the  protein  structure  and  conformation,
which negatively impacts the mitochondrial inner and outer
membrane  functions.  The  alteration  in  mitochondria  may
subsequently lead to differential effects on ROS and ATP
generation, Ca2+ levels in cytoplasm and mitochondria, and
ΔΨm in TM cells.
In  conclusion,  we  present  strong  evidence  of  the
association  of  myocilin  with  mitochondria.  Increased
generation of ROS, decreased ATP production, decreased
ΔΨm, and increased Ca2+ levels in both the cytoplasm and
mitochondria in TM cells with Pro370Leu mutant myocilin
gene transfection indicate that Pro370Leu mutant myocilin
can affect mitochondria functions. The mutation increases
vulnerability in the mitochondria to various cellular injuries
and disables normal human TM cells functions, which may
eventually contribute to the failure of the TM to control IOP.
New insights on the protective effects of antioxidants and
mitochondria permeability transition inhibitors to the health
of TM cells [18,46] suggest that there are POAG treatment
possibilities that are worthy of further investigation.
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